Analysts Set Expectations for Ascendis Pharma A/S’s Q1 2018 Earnings (ASND)

Ascendis Pharma A/S (NASDAQ:ASND) – Equities research analysts at Wedbush issued their Q1 2018 EPS estimates for shares of Ascendis Pharma A/S in a report issued on Thursday. Wedbush analyst L. Moussatos expects that the firm will post earnings per share of ($0.54) for the quarter. Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. Wedbush also issued estimates for Ascendis Pharma A/S’s Q2 2018 earnings at ($0.55) EPS, Q3 2018 earnings at ($0.58) EPS, Q4 2018 earnings at ($0.55) EPS and FY2021 earnings at $5.90 EPS.

Several other equities research analysts have also issued reports on ASND. Leerink Swann reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, December 1st. Zacks Investment Research raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating and set a $23.00 price objective for the company in a research note on Monday, November 28th. Finally, Credit Suisse Group AG assumed coverage on Ascendis Pharma A/S in a research note on Thursday, February 9th. They issued an “outperform” rating and a $28.00 price objective for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $29.00.

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

COPYRIGHT VIOLATION NOTICE: “Analysts Set Expectations for Ascendis Pharma A/S’s Q1 2018 Earnings (ASND)” was originally published by Mideast Time and is owned by of Mideast Time. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.mideasttime.com/analysts-set-expectations-for-ascendis-pharma-ass-q1-2018-earnings-asnd/1588945.html.

Shares of Ascendis Pharma A/S (NASDAQ:ASND) opened at 28.27 on Monday. The stock’s market capitalization is $712.66 million. The company has a 50-day moving average price of $27.64 and a 200 day moving average price of $22.09. Ascendis Pharma A/S has a 52 week low of $11.92 and a 52 week high of $30.57.

Several large investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $1,772,000. Foresite Capital Management III LLC bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $3,643,000. Eventide Asset Management LLC bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $4,635,000. Sphera Funds Management LTD. raised its stake in Ascendis Pharma A/S by 0.6% in the third quarter. Sphera Funds Management LTD. now owns 263,500 shares of the company’s stock valued at $5,296,000 after buying an additional 1,700 shares during the last quarter. Finally, Acuta Capital Partners LLC raised its stake in Ascendis Pharma A/S by 58.5% in the fourth quarter. Acuta Capital Partners LLC now owns 575,309 shares of the company’s stock valued at $11,644,000 after buying an additional 212,309 shares during the last quarter. 44.51% of the stock is owned by institutional investors and hedge funds.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

5 Day Chart for NASDAQ:ASND

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.